Clinical Trials Logo

Ocular Pain clinical trials

View clinical trials related to Ocular Pain.

Filter by:
  • None
  • Page 1

NCT ID: NCT05626478 Recruiting - Corneal Edema Clinical Trials

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

NCT ID: NCT04975971 Completed - Cataract Senile Clinical Trials

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

Start date: March 9, 2021
Phase:
Study type: Observational

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery

NCT ID: NCT04521140 Completed - Clinical trials for Intraocular Pressure

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

Start date: October 16, 2020
Phase: Phase 4
Study type: Interventional

Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg insert following corneal transplant surgery (PKP, DSEK, DMEK) as compared to topical prednisolone acetate 1%.

NCT ID: NCT03521791 Completed - Pterygium Clinical Trials

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

PRO-155/IV
Start date: December 13, 2017
Phase: Phase 4
Study type: Interventional

Title of the study Efficacy and safety of PRO-155 (Zebesten ofteno®) on inflammation of the conjunctival surface in subjects with grade I-III pterygium vs placebo. Hypothesis H0. The Zebesten® ophthalmic solution (bromfenac 0.09%) is less effective and safe than placebo in reducing conjunctival hyperemia in subjects with grade I-III pterygium. H1 The Zebesten® ophthalmic solution (bromfenac 0.09%) is more effective and safe than placebo in reducing conjunctival hyperemia in subjects with grade I-III pterygium. Objective To evaluate the efficacy and safety of PRO-155 (bromfenac 009%) ophthalmic solution in the treatment of conjunctival hyperemia and ocular surface inflammation in a clinical model of pterygium grade I to III.

NCT ID: NCT02455999 Completed - Dry Eye Syndrome Clinical Trials

Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain

Start date: June 2015
Phase: Phase 2
Study type: Interventional

The aim of this pilot study is to compare the analgesic effect of two strengths of SYL1001 eye drops versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.

NCT ID: NCT02128113 Completed - Cataract Surgery Clinical Trials

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Start date: May 31, 2014
Phase: Phase 2
Study type: Interventional

This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.

NCT ID: NCT01776658 Completed - Dry Eye Syndrome Clinical Trials

Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain

Start date: November 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this pilot study is to compare the analgesic effect of SYL1001 versus placebo in patients with ocular pain associated with Dry Eye Syndrome. General and local tolerability are also evaluated.

NCT ID: NCT01438281 Completed - Dry Eye Clinical Trials

Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Start date: July 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether SYL1001 is safe for the prevention and treatment of ocular pain and dry eye syndrome.